Fiche centre
Kyushu University Hospital
Fukuoka — Japan
Essais liés12clinical trials
VilleFukuokalocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07164443
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ipatasertib | Cancer | Phase 3 | NCT05862285 | UmbrellaMAX — A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | RECRUITING |
| Pumitamig | Cancer | Phase 1/2 | NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | RECRUITING |
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | RECRUITING |
| Epcoritamab | SEP | Phase 2 | NCT05660967 | EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | TERMINATED |
| Pasritamig | Cancer | Phase 3 | NCT07164443 | KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| Adagrasib | Cancer | Phase 3 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | ACTIVE_NOT_RECRUITING |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | COMPLETED |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |